Business Wire

A New Sense, “Ninja Experience” Fusing the Real and the Virtual World.“VR NINJA DOJO” Entertaining Adults and Children Has Appeared!

6.3.2019 07:58:00 EET | Business Wire | Press release

Share

Five for Co., Ltd. (Location: Chiyoda-ku Ward, Tokyo, Representative Director: Takayoshi Tanigawa) will open a VR experience entertainment facility, “VR NINJA DOJO” which provides Ninja experience for foreigners visiting Japan on Monday, March 18th, 2019 in Uchikanda, Chiyoda-ku, Tokyo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190305006076/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Interior view of VR NINJA DOJO (Photo: Business Wire)

VR NINJA DOJO is an entertainment facility that provides “Ninja Experience” fusing the real and virtual world for foreigners visiting Japan. One of Japanese cultures, “Ninja”, is also literally popular as “Ninja” overseas. The facility is designed with the stylistic beauty inherent in Japan and is a space where you can feel the unique perspective of the Japan world. Also, this facility is designed with our own technology so that the third parties who do not wear a head-mount display can enjoy the virtual world as well. So, you can unite and enjoy the experience even when your group consists of two or more people. Furthermore, since we explain the operation completely in English, foreigners visiting Japan comfortably use the facility. Visitors will take the full proficiency examination to be a Ninja master through the VR experience after they had realistic discipline and training by doing physical activities.

Recently, the number of foreign visitors has been on the rise in Japan. According to Japan National Tourism Organization (JNTO), the total number of foreign visitors to Japan in 2018 exceeded 30,010,000, which is the first time ever recorded over 30 million people and is an increase of 8.7% from the previous year. It is expected that the number of foreign visitors to Japan will further increase by 2020, but there is some change in their consumption behavior. In the past, "entity-oriented consumption" such as purchasing large quantities of home appliances and cosmetics etc. was mainstream. But, as the EC industry has expanded, there is less value in traveling some places in order to purchase goods there. Instead, "situation-oriented consumption" such as taking experience type services including hot spring tours and kimono experiences is on the increase. The new facility in anticipation of the growing inbound demand provides a new entertainment that will definitely become popular among foreign visitors to Japan.

VR NINJA DOJO provides a Ninja experience, which is only available here, with the concept of “The Hospitality of Japanese Culture in both the 'real' and the 'virtual' world."

 

[Contents of the Experience]

The required time for a Ninja Experience is from 75 minutes to 90 minutes, and up to 10 persons in one group can participate.
Ninja cosplay experience
- Ninja discipline and training in the real and the virtual world
- Full proficiency examination (VR experience)
- VR ceremonial photograph
- Presentation of handscroll type certificate
 
 

[Details of the Facility]

The Name of the Facility:

 

VR NINJA DOJO

Opening Date:

March 18th, 2019

Location of the Facility:

Takebashi Bldg. 1F, 2-15-15 Uchikanda, Chiyoda-ku,

Tokyo 101-0047

Eligible Person for the Experience: Foreign residents and tourists in Japan

- One accompanying Japanese person per a foreigner is free of charge.

(Ninja costume and the handscroll type certificate are not included.)

- There is a special plan available catering to Japanese only.

Official Site:

https://vr-ninja.jp/

 
 

[Company Profile]

Company Name:

 

Five for Co., Ltd.

Date of Establishment:

March 14th, 2017

Representative Director:

Takayoshi Tanigawa

Location:

Uchikanda Chuo Bldg. 7F, 1-18-13 Uchikanda,

Chiyoda-ku, Tokyo 101-0047

Business Description:

VR Entertainment Content Produce & Development

 

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

VR NINJA DOJO PR SBY Co., Ltd. Inada / Arai
(Antil Co., Ltd. Akazaki Ichika / Sato Katsuhiko / Yoshida Yusei)
TEL: (+81) 3-5572-6061
FAX: (+81) 3-6685-5267
E-mail: vr_ninjadojo@vectorinc.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye